ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRME vs DNA // GROSS PROFIT MARGIN

Prime Medicine Inc. (NASDAQ) VS. Ginkgo Bioworks Holdings Inc. (Class A) (NYSE) • 15-METRIC TALLY: PRME 5 — DNA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRME VS. DNA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRME DNA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -17.58% -21.80% +4.22 PRME /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -0.20% -59.80 DNA /net-margins <GO>
Revenue Growth (YoY) 55.30% -25.10% +80.40 PRME /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 PRME /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.3 58.4 +7.90 PRME /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $950.4M $819.7M $130.7M PRME /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRME REV DNA REV PRME GROSS % DNA GROSS % PRME FCF DNA FCF
FY 2025 $4.6M $170.2M — — -$167.1M -$178.7M
FY 2024 $3.0M $227.0M — — -$130.2M -$382.1M
FY 2023 $0 $251.5M — — -$165.4M -$295.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRME // BETA —
DNA // BETA —